Overview

Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerance of a rush build up administration of Depigoid forte pollen and the first maintenance dose administered 4 weeks later.
Phase:
Phase 2
Details
Lead Sponsor:
Laboratorios Leti, S.L.